Comorbidities, Dosing Issues, Polypharmacy, and Adverse Effects in Breast Cancer
The goal of this initiative is to increase awareness, knowledge, and competence in the need for culturally sensitive, evidence-based, guideline recommended approaches for the treatment of breast cancer in Black patients.
Category
  • Breast Cancer
  • Disparities
Format
  • Enduring Activity
Credits
  • 0.50 AAPA Category 1 CME credit
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
Prostate Cancer in Black Individuals: How Can We Do Better?
The goal of this initiative is to increase awareness, knowledge, and competence in the need for culturally sensitive, evidence-based, guideline recommended approaches for the treatment of prostate cancer in Black patients.
Category
  • Disparities
  • Prostate Cancer
Format
  • Enduring Activity
Credits
  • 0.50 AAPA Category 1 CME credit
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
Comorbidities, Dosing Issues, Polypharmacy, and Adverse Effects in Prostate Cancer
The goal of this initiative is to increase awareness, knowledge, and competence in the need for culturally sensitive, evidence-based, guideline recommended approaches for the treatment of prostate cancer in Black patients.
Category
  • Disparities
  • Prostate Cancer
Format
  • Enduring Activity
Credits
  • 0.50 AAPA Category 1 CME credit
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
Plenary Session: Best Practices for Addressing the Health Needs of the LGBTQ+ Community in Oncology Care
In 2022, NCCN conducted a patient advocacy scan with roughly a dozen representatives from the LGBTQ+ community representing patient advocates, researchers, and healthcare providers with expertise in this area. The results of the scan found that patients who are LGBTQ+ are likely to report experiencing bias and discrimination in care which can impact their care outcomes.
Category
  • Disparities
  • Supportive Care Topics
Format
  • Recorded Webcast
Credits
  • 1.50 AAPA Category 1 CME credit
  • 1.50 ACPE contact hours
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 ANCC contact hours
  • 1.50 ASWB continuing education credit
  • 1.50 Participation
Cancer Screening in Underrepresented Populations
All individuals, regardless of their race, socioeconomic status, or gender identity deserve the best chance at beating cancer.
Category
  • Disparities
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 ASWB continuing education credit
  • 1.00 Participation
Mobile Screening Programs: Improving Patient Access to Oncology Care
It is important for cancer centers that are interested in developing mobile screening programs at their respective institutions to be informed about issues and challenges experienced in the development of successful mobile screening programs.
Category
  • Disparities
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Social Determinants of Health: Collection, Integration, and Intervention
Education in the topic of social determinants of health is important to improve oncology care because a robust process of assessing need, integrating screening tools in the electronic health record, and connecting oncology patients with appropriate services is key to ensuring accessible and equitable cancer care.
Category
  • Best Practices
  • Disparities
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 ASWB continuing education credit
  • 1.00 Participation
Disparities in Breast Cancer Screening and Management
Clinicians need to recognize that these disparities exist and the causes for the disparities to optimally manage their patients with breast cancer.
Category
  • Breast Cancer
  • Disparities
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
Navigating the Challenges: Effective Management of Toxicities in CAR T-Cell Therapies
While cytokine release syndrome and neurotoxicity are widely reported as the most common acute CAR T-cell toxicities, it is essential for providers to understand that CAR T-cell therapy may also result in other toxicities (such as infections, cytopenias, or B-cell aplasia), some of which could persist for months to years after infusion.
Category
  • Management of Immunotherapy-Related Toxicities
  • Multiple Myeloma
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Revolutionizing Hematologic Cancer Treatment: The Promise of Bispecific T-Cell Engagers
Bispecific T-cell engagers are emerging as promising treatment options for patients with heavily pretreated multiple myeloma and B-cell lymphomas, especially for patients with disease relapse following CAR T-cell therapy. Careful monitoring of adverse events and implementing appropriate supportive care strategies is important to maximize the clinical benefit associated with bispecific T-cell engager therapy.
Category
  • Multiple Myeloma
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation

Pages